PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target

Hypofibrinolysis is a key abnormality in diabetes and contributes to the adverse vascular outcome in this population. Plasminogen activator inhibitor (PAI)-1 is an important regulator of the fibrinolytic process and levels of this antifibrinolytic protein are elevated in diabetes and insulin resista...

Full description

Bibliographic Details
Main Authors:	Rawan Altalhi, Nikoletta Pechlivani, Ramzi A. Ajjan
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	International Journal of Molecular Sciences
Subjects:	plasminogen activator inhibitor 1 (PAI-1) PAI-1 inhibitors diabetes hypofibrinolysis cardiovascular disease therapeutics
Online Access:	https://www.mdpi.com/1422-0067/22/6/3170

Similar Items

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition
by: Machteld Sillen, et al.
Published: (2020-12-01)

Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model
by: Hideki Furuya, et al.
Published: (2020-02-01)

Studies on Inhibitors of Plasminogen Activator Inhibitor-1(PAI-1) and Inhibitors of PAI-1 Production as Antithrombotic Agents
by: Miyazaki, Hiroshi
Published: (2010)

Structural Insight into the Two-Step Mechanism of PAI-1 Inhibition by Small Molecule TM5484
by: Machteld Sillen, et al.
Published: (2021-02-01)

A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?
by: Machteld Sillen, et al.
Published: (2021-03-01)

Impact of type and duration of use of antipsychotic drugs on plasma levels of selected acute-phase proteins in patients with major mental illnesses
by: Sheu Kadiri Rahamon, et al.
Published: (2020-01-01)

PLASMINOGEN ACTIVATOR INHIBITOR GENE POLYMORPHISM IN EVALUATION OF THE VARIOUS LOCALIZATION THROMBOSIS RISKS (PILOT STUDY)
by: A. I. Subbotovskaya, et al.
Published: (2015-10-01)

The prevalence of PAI-1 4G/5G gene variant in Serbian population
by: Đorđević Valentina, et al.
Published: (2013-01-01)

Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study
by: Yousef AA, et al.
Published: (2020-12-01)

Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study [Corrigendum]
by: Yousef AA, et al.
Published: (2021-02-01)

Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb Zanthoxylum nitidum var. tomentosum
by: Bo Yu, et al.
Published: (2017-07-01)

Association Between PAI-1 Activity Levels and t-PA Antigen with Glycemic Status in Prediabetic Population
by: Andi Fachruddin Benyamin, et al.
Published: (2016-11-01)

Association of Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms with Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women
by: Jung Oh Kim, et al.
Published: (2016-12-01)

Chronic Thromboembolic Pulmonary Hypertension Secondary to Thrombophilia and Incidentally Diagnosed Atrial Septal Defect
by: Mehmet Kilinc, MD, et al.
Published: (2020-04-01)

The prevalence of PAI-1 4G/5G polymorphism in women with fetal loss: First data for a Serbian population
by: Đorđević Valentina, et al.
Published: (2014-01-01)

Effect of Fagonia arabica on thrombin induced release of t-PA and complex of PAI-1 tPA in cultured HUVE cells
by: Prutha D. Aloni, et al.
Published: (2016-07-01)

Fibrinolytic System Changes in Liver Surgery: A Pilot Observational Study
by: Agnese Ozolina, et al.
Published: (2018-09-01)

Serpins in Hemostasis as Therapeutic Targets for Bleeding or Thrombotic Disorders
by: Elsa P. Bianchini, et al.
Published: (2021-01-01)

Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women
by: Merih Ozgen, et al.
Published: (2012-11-01)

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
by: Waschki B, et al.
Published: (2017-03-01)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
by: Niaz Mahmood, et al.
Published: (2018-02-01)

Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease
by: Wang H, et al.
Published: (2016-09-01)

Activated protein C plays no major roles in the inhibition of coagulation or increased fibrinolysis in acute coagulopathy of trauma-shock: a systematic review
by: Satoshi Gando, et al.
Published: (2018-06-01)

MiR145-5p inhibits proliferation of PMVECs via PAI-1 in experimental hepatopulmonary syndrome rat pulmonary microvascular hyperplasia
by: Yang Chen, et al.
Published: (2019-11-01)

Histone deacetylase 2 (HDAC2) attenuates lipopolysaccharide (LPS)-induced inflammation by regulating PAI-1 expression
by: Wen-Feng Fang, et al.
Published: (2018-01-01)

The Central Role of Fibrinolytic Response in COVID-19—A Hematologist’s Perspective
by: Hau C. Kwaan, et al.
Published: (2021-01-01)

Genetic Background of a Recurrent Unusual Combined Form of Retinal Vein Occlusion: A Case Report
by: Kajo Bucan, et al.
Published: (2018-04-01)

Rôle de l'inhibiteur de l'activateur tissulaire du plasminogène de type 1 (PAI-1) dans la dépression majeure chez la souris
by: Party, Helene
Published: (2017)

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
by: Sakamoto Masaya, et al.
Published: (2012-08-01)

Ischemic stroke in patients with type 2 diabetes: Relationship between decreased insulin sensitivity and fibrinolysis impairment
by: Jotić Aleksandra, et al.
Published: (2011-01-01)

Le facteur 4 plaquettaire (PF4/CXCL4) prévient la formation du complexe initial de l’inhibiteur de l’activateur du plasminogène (PAI-1) avec sa cible d’origine tissulaire (t-PA)
by: Libraire, Julie
Published: (2012)

SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma
by: Minori Tsuge, et al.
Published: (2018-03-01)

Plasminogen activator inhibitor-1 gene polymorphism as a risk factor for vascular complications in type 2 diabetes mellitus
by: Fatma A. Khalaf, et al.
Published: (2019-10-01)

Perubahan Kendali Glikemik dan Plasminogen Activator Inhibitor-1 (PAI-1) pada Penyandang Diabetes Melitus Tipe-2 yang Berpuasa Ramadhan di RSUPN Cipto Mangunkusumo
by: Khomimah Khomimah, et al.
Published: (2014-07-01)

Osteonecrosis of the Femoral Head in Patients with Hypercoagulability—From Pathophysiology to Therapeutic Implications
by: Elena Rezus, et al.
Published: (2021-06-01)

Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma
by: Gary Tincknell, et al.
Published: (2021-08-01)

Pulmonary Embolism and Severe Asthma: Case Report and Literature Review
by: Po-Hsin Lee, et al.
Published: (2019-09-01)

Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis
by: Okuda Y, et al.
Published: (2016-04-01)

Fibrin γ/γ' influences the secretion of fibrinolytic components and clot structure
by: Miriam Cantero, et al.
Published: (2019-11-01)

A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease
by: Gael B. Morrow, et al.
Published: (2021-04-01)